These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 11371747)

  • 1. Multiple sclerosis: recent developments in neuropathology, pathogenesis, magnetic resonance imaging studies and treatment.
    Lucchinetti C; Brück W; Noseworthy J
    Curr Opin Neurol; 2001 Jun; 14(3):259-69. PubMed ID: 11371747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Key issues in the diagnosis and treatment of multiple sclerosis. An overview.
    O'Connor P;
    Neurology; 2002 Sep; 59(6 Suppl 3):S1-33. PubMed ID: 12448786
    [No Abstract]   [Full Text] [Related]  

  • 3. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis.
    Dhib-Jalbut S
    Neurology; 2002 Apr; 58(8 Suppl 4):S3-9. PubMed ID: 11971121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Possibilities and limits of immunotherapy in multiple sclerosis. Inflammatory and degenerative aspects of the disease require a new pathogenetic concept].
    Kornhuber ME; Zierz S
    Nervenarzt; 2003 Jun; 74(6):537-8; discussion 539. PubMed ID: 12799792
    [No Abstract]   [Full Text] [Related]  

  • 5. To treat, or not to treat: the therapeutic dilemma of idiopathic monosymptomatic demyelinating syndromes.
    Frohman EM; Racke M; van Den Noort S
    Arch Neurol; 2000 Jul; 57(7):930-2. PubMed ID: 10891973
    [No Abstract]   [Full Text] [Related]  

  • 6. Multiple Sclerosis.
    Reich DS; Lucchinetti CF; Calabresi PA
    N Engl J Med; 2018 Jan; 378(2):169-180. PubMed ID: 29320652
    [No Abstract]   [Full Text] [Related]  

  • 7. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pathogenesis and treatment of multiple sclerosis (state of the art in 2000)].
    Zavalishin IA; Zhuchenko TD; Peresedova AV
    Vestn Ross Akad Med Nauk; 2001; (7):18-22. PubMed ID: 11523422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Newer long-term treatments for multiple sclerosis.
    Pryse-Phillips W
    Clin Neurol Neurosurg; 2002 Jul; 104(3):265-71. PubMed ID: 12127666
    [No Abstract]   [Full Text] [Related]  

  • 11. [Recommendations for the use of immunomodulatory drugs in multiple sclerosis: the BCTRIMS consensus] [Brazilian Committee for Treatment and Research in Multiple Sclerosis].
    Tilbery CP; Moreira MA; Mendes MF; Lana-Peixoto MA
    Arq Neuropsiquiatr; 2000 Sep; 58(3A):769-76. PubMed ID: 10973126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Multiple sclerosis (MS), an inflammatory or degenerative disease?].
    Confavreux C; Vukusic S
    Presse Med; 2004 Feb; 33(3):151-2. PubMed ID: 15029024
    [No Abstract]   [Full Text] [Related]  

  • 13. Disease modifying treatment in multiple sclerosis.
    Fuller GN; Bone I
    J Neurol Neurosurg Psychiatry; 2001 Dec; 71 Suppl 2(Suppl 2):ii20-1. PubMed ID: 11701780
    [No Abstract]   [Full Text] [Related]  

  • 14. Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses.
    Beck RW; Chandler DL; Cole SR; Simon JH; Jacobs LD; Kinkel RP; Selhorst JB; Rose JW; Cooper JA; Rice G; Murray TJ; Sandrock AW
    Ann Neurol; 2002 Apr; 51(4):481-90. PubMed ID: 11921054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Why treat early multiple sclerosis patients?
    Comi G
    Curr Opin Neurol; 2000 Jun; 13(3):235-40. PubMed ID: 10871245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The treatment of multiple sclerosis: current and future.
    Polman CH; Hartung HP
    Curr Opin Neurol; 1995 Jun; 8(3):200-9. PubMed ID: 7551119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain atrophy, interferon beta, and treatment trials in multiple sclerosis.
    Miller DH
    Lancet; 2004 Oct 23-29; 364(9444):1463-4. PubMed ID: 15500870
    [No Abstract]   [Full Text] [Related]  

  • 18. Options for multiple sclerosis therapy.
    Cotton P
    JAMA; 1994 Nov; 272(18):1393. PubMed ID: 7933404
    [No Abstract]   [Full Text] [Related]  

  • 19. [Early immunomodulatory treatment of multiple sclerosis: pros and cons].
    Wender M
    Neurol Neurochir Pol; 2003; 37(4):777-82. PubMed ID: 14746238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature.
    Mahurkar S; Suppiah V; O'Doherty C
    Autoimmun Rev; 2014 Feb; 13(2):178-86. PubMed ID: 24189284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.